Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”

Схожие документы

• Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial
  по: Dear, James
  Опубликовано: (2019)
• Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)
  по: Morrison, Emma E., et al.
  Опубликовано: (2019)
• Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?
  по: Karlsson, Jan Olof G.
  Опубликовано: (2019)
• Novel acetylcysteine regimens for treatment of paracetamol overdose
  по: Waring, W. Stephen
  Опубликовано: (2012)
• Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose
  по: Pettie, Janice M., et al.
  Опубликовано: (2019)